NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals
Rhea-AI Summary
NorthStrive Biosciences (Nasdaq: ELAB) filed ten U.S. patent applications on Feb. 19, 2026, extending its EL-22 and EL-32 technologies into animal health and agricultural markets.
The filings cover muscle growth and yield in livestock and poultry, aquaculture growth and emissions reduction, and list ten U.S. application numbers for EL-22 and EL-32.
Positive
- Ten U.S. patent applications filed for EL-22 and EL-32 on Feb. 19, 2026
- Coverage across sectors: livestock, aquaculture, and poultry applications broaden addressable markets
- Multiple use cases: muscle growth, yield improvement, and emissions-reduction applications
Negative
- Applications not grants: filings are patent applications and do not guarantee issued patents
Market Reaction
Following this news, ELAB has gained 9.76%, reflecting a notable positive market reaction. Argus tracked a peak move of +14.3% during the session. Our momentum scanner has triggered 17 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $1.35. This price movement has added approximately $355K to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves: SPRC -4.97%, REVB +2.17%, INDP -0.37%, QLGN +7.72%, UBX -29.14%. Momentum scanner flags 2 Argus peers (ENVB +2.23%, GLTO +5.90%) moving up, alongside 1 down-mover (DRMA -3.13%), suggesting broader biotech activity rather than a purely isolated move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Animal health license | Positive | -0.6% | Exclusive license of EL-22 and EL-32 programs for non-human animal health. |
| Feb 04 | AI program update | Neutral | +0.0% | Timeline update and model upgrades for Phase III AI-driven drug discovery. |
| Feb 03 | Machining acquisition | Positive | -40.0% | Completed SVM Machining acquisition to expand precision manufacturing platform. |
| Jan 06 | Nuclear stake deal | Positive | -12.7% | Non-controlling equity stake in Nuclea Energy’s MMR-focused nuclear platform. |
| Jan 05 | Reverse stock split | Negative | +13.4% | 1-for-4 reverse split to consolidate shares and adjust capital structure. |
Recent news often saw negative or muted price reactions, including declines after acquisitions and licensing, with only the reverse stock split drawing a positive move.
Over the last few months, ELAB has announced multiple strategic steps, including a 1-for-4 reverse stock split on Jan 6, 2026, acquisitions in precision machining and a stake in Nuclea Energy, and a definitive license for EL-22/EL-32 in animal health. Despite generally constructive corporate actions, four of the last five releases saw negative price reactions. Today’s patent filings extend the EL-22/EL-32 animal-health IP footprint following the recent licensing agreement.
Market Pulse Summary
The stock is up +9.8% following this news. A strong positive reaction aligns with the company’s push to expand EL-22 and EL-32 into animal health and agricultural markets. Investors previously saw mixed price responses to licensing and acquisition news, so a large move on these 10 new U.S. patent applications could reflect renewed focus on IP optionality rather than fundamentals alone and may remain sensitive to financing structures disclosed in recent SEC filings.
Key Terms
u.s. patent applications regulatory
aquaculture technical
AI-generated analysis. Not financial advice.
NEWPORT BEACH, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences, Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced the filing of ten (10) new U.S. patent applications expanding its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, including applications designed to encourage animals to grow new muscle and increase muscle weight return per animal.
These ten (10) patent applications include five (5) new patent applications covering EL-22 and five (5) new, corresponding applications covering EL-32 across multiple farmed animal categories, including livestock, aquaculture, and poultry.
Muscle Growth and Increased Yield in Livestock
Two of the patent applications cover the use of EL-22 and EL-32 as non-feed additive supplements designed to encourage animals to grow new muscle tissue and increase muscle weight return per animal.
- EL-22 – U.S. Application No. 19/541,209
- EL-32 – U.S. Application No. 19/540,888
Livestock Emissions Reduction and Animal Health
Additional applications cover the use of EL-22 and EL-32 to reduce gaseous emissions in livestock, potentially decreasing environmental impact and mitigating ruminal tympany risk.
- EL-22 – U.S. Application No. 19/540,893
- EL-32 – U.S. Application No. 19/540,895
Aquaculture Muscle Growth and Efficiency
Applications have also been filed covering the use of EL-22 and EL-32 in aquaculture to encourage muscle growth in aquatic species, potentially reducing time to commercially viable size and lowering energy expenditures.
- EL-22 – U.S. Application No. 19/540,898
- EL-32 – U.S. Application No. 19/540,900
Aquaculture Emissions Reduction
Additional aquaculture filings address emissions reduction to mitigate eutrophic conditions.
- EL-22 – U.S. Application No. 19/540,905
- EL-32 – U.S. Application No. 19/540,908
Poultry Muscle Development
The final set of applications covers the use of EL-22 and EL-32 in poultry to encourage muscle growth and improve muscle yield per bird within standard growth timelines.
- EL-22 – U.S. Application No. 19/540,913
- EL-32 – U.S. Application No. 19/540,918
About NorthStrive Biosciences Inc.
NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. NorthStrive’s lead asset, EL-22, leverages an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
FAQ
What did NorthStrive (ELAB) announce on Feb. 19, 2026 about EL-22 and EL-32?
Which animal sectors do EL-22 and EL-32 patent applications for ELAB target?
Do the EL-22 and EL-32 filings claim to increase animal muscle and yield for ELAB?
What environmental uses are included in ELAB's patent filings for EL-22 and EL-32?
Are the U.S. patent application numbers for ELAB's EL-22 and EL-32 disclosed?
